The global fampridine market is expected to grow at a significant CAGR during the forecast period (2021-2027). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, to remain competitive in the marketplace. For instance, Bojian Company announced in May, 2021 that Fampridine Sustained-Release Tablets have been approved by the National Medical Products Administration, China, for the treatment of multiple sclerosis (MS) in adult patients with a walking disorder. Fampridine sustained-release pills are the first medication for adult MS patients in China to enhance their walking capacity. The first batch of clinically urgently needed international new medications includes fampridine sustained-release pills.
The National Medical Products Administration accepted its new medication marketing application in January 2021, and it was included in the priority review and approval procedure in April 2021. Three global phase 3 randomized, double-blind, placebo-controlled trials were mentioned in the National Medical Products Administration’s drug review. The results showed that patients who were given fampridine sustained-release pills had much faster walking speeds than those who were given a placebo. Furthermore, Fampridine Sustained-Release Tablets have a quick therapeutic reaction time, with the curative impact appearing few weeks after the treatment begins. MS was added to the “First List of Rare Diseases” in May 2018. According to the data published by the National MS Society of Canada in September 2020, 2.8 million people across the globe have multiple sclerosis (MS). That implies someone with MS is diagnosed every 5 minutes somewhere on the planet. The majority of people with MS are diagnosed between the ages of 20 and 50, and women are three times more likely than males to have the disease. This, in turn, is accelerating the growth of the global fampridine market.
To Request a Sample of our Report on Fampridine Market: https://www.omrglobal.com/request-sample/fampridine-market
Moreover, in December 2018, Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., launched Dalfampridine Extended-release Tablets, 10 mg, the generic pharmaceutical equivalent to Ampyra, according to Hikma Pharmaceuticals PLC. Dalfampridine Extended-release Tablets are used to support adults with multiple sclerosis improve their walking by increasing their walking pace. Hikma was one of the first ANDA applicants to submit a paragraph IV certification disputing the validity of patents mentioned for Ampyra tablets, 10 mg, and is thus entitled for 180 days of generic medication exclusivity. Hikma was one of two generic producers who failed not reach an agreement with Acorda Therapeutics among the ten first-filers. According to Acorda Therapeutics’ 2017 annual report, Ampyra sales in the US accounted for $543 million in 2017, up 10% from 2016.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
- By Form
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Biogen Inc., Acorda Therapeutics, Inc., and Hikma Pharmaceuticals plc, among others.
(Get 15% Discount on Buying this Report)
A full Report of Fampridine Market is Available @ https://www.omrglobal.com/industry-reports/fampridine-market
Global Fampridine Market Report by Segment
By Type
- Purity: 95%
- Purity: >95%
By Form
- Branded
- Generic
Global Fampridine Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
